Understand dealer-level and representative-level product due diligence for derivatives, including product structure, risks, costs, serviceability, and escalation triggers.
Product due diligence and know-your-product for derivatives appears in the official CIRO Derivatives Exam syllabus as part of The client relationship. Questions here usually test whether you can identify the controlling rule, control, calculation, workflow, or escalation path in a realistic fact pattern rather than simply restate a definition.
Derivatives know-your-product work is not finished when a product is listed or when a representative has seen it before. The firm must understand what the product is, how it behaves, how it is valued, what operational support it needs, and what can go wrong in stressed conditions. The representative must then understand enough to explain it accurately, use it in the right circumstances, and recognize when it exceeds the firm’s approved product scope or the client’s needs.
That distinction matters on the exam. A fact pattern may describe a product that the representative likes, but the right answer is still to stop if the dealer cannot price, monitor, margin, disclose, or supervise it properly.
| Review area | What the firm needs to understand | Why it matters |
|---|---|---|
| Structure and payoff | Underlying interest, trigger events, settlement method, exercise or expiry features | Without structure knowledge, the firm cannot explain likely outcomes or supervise use |
| Valuation and liquidity | How the product is priced, how often it can be marked, how easily it can be closed or transferred | Weak pricing or liquidity turns a recommendation and reporting problem into a control problem |
| Margin and collateral | Initial margin, variation margin, collateral calls, concentration effects, offset treatment | Margin pressure can change the real risk of the strategy very quickly |
| Risks | Market risk, leverage, volatility, basis risk, gap risk, counterparty risk, operational risk | The product may be inappropriate even when the market view is reasonable |
| Costs | Commissions, spreads, financing, embedded structuring costs, carry, unwind costs | A product can be economically unattractive even if it is technically permitted |
| Operational support | Documentation, approvals, systems, statements, confirmations, exception monitoring | If the firm cannot service the product, it should not offer it |
The exam often expects you to notice that product due diligence is not identical across all derivative families:
The stronger answer explains how the product family changes the due-diligence focus instead of pretending every derivative can be reviewed using one generic checklist.
You should be ready to escalate before offering derivative trading services when any of these are true:
That is why the exam often rewards answers that delay or refuse availability until understanding is sufficient. In a derivatives context, incomplete product understanding is not a minor training gap. It is a client-protection and supervision problem.
The stronger answer separates dealer-level approval from representative-level use. It then tests whether the product can be understood, explained, serviced, monitored, and reported before it asks whether the product sounds attractive.
A representative wants to recommend a customized OTC derivative that seems to fit the client’s market view, but the firm does not yet have a reliable valuation method or a clear process for ongoing statement disclosure. What is the best response?
The strongest answer is to escalate and withhold the product until the firm can value, supervise, and service it properly. A good market thesis does not cure weak product due diligence.